O

OneOncology

Operates network of community oncology practices

Senior Director - Site Engagement

Full-Time
No salary listed
Senior, Expert
Bachelor's, Master's
Remote in USA
Remote
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A bachelor’s degree in a healthcare-related field is required.
  • At least 8 years of experience in clinical research with significant site-level leadership experience is required; oncology experience is preferred.
  • Direct, hands-on site-level experience as a site research manager or site director is required.
  • Demonstrated experience with patient enrollment strategy and patient recruitment in community research settings is required; oncology experience is preferred.
  • Experience managing or supporting multiple research sites or regions simultaneously is required.
  • Strong understanding of good clinical practice, regulatory requirements, and ethical standards is required.
  • Deep understanding of clinical research operations within community oncology practice settings is required.
  • Demonstrated ambition to grow and scale site-based clinical research programs is required.
  • Executive presence and the ability to establish trust, authority, and respect with independent physicians, practice leaders, and senior stakeholders through knowledge, consistency, and character are required.
  • Strong working knowledge of site-level regulatory, financial, and operational requirements is required.
  • Experience serving as a single point of accountability for external stakeholders, including sites, sponsors, and principal investigators, is required.
  • Ability to build trust and effective partnerships with physicians and site staff is required.
  • Proven experience improving site performance, enrollment, and operational efficiency is required.
  • Excellent communication, coaching, and change-management skills are required.
Responsibilities
  • Provide strategic and operational leadership for assigned site- and study-operations functions by establishing accountabilities, performance expectations, operating practices, and priorities aligned with organizational goals.
  • Serve as the senior operational relationship leader for community practices, building partnerships with practice leadership, investigators, and research teams and ensuring site needs are coordinated and addressed.
  • Lead, coach, and develop the Site Network Manager team and other assigned operational staff.
  • Design and implement a scalable site-support model based on practice maturity, performance, complexity, growth objectives, and support needs, including engagement cadences, service expectations, and escalation pathways.
  • Assess site-level research infrastructure and support sites with space planning, vendor management, and operational workflows to drive growth or improve research efficiency.
  • Partner with site physician and operational leadership to develop and implement staffing plans and staff training supporting research growth.
  • Partner with the Program Management team and Site Physician Leadership to align each site’s trial menu with operational capabilities, performance goals, and patient population.
  • Establish accountability for site and study performance, including readiness, enrollment, study delivery, quality, financial sustainability, relationship health, and resolution of operational issues.
  • Identify barriers to patient identification, enrollment, and study execution; convene stakeholders, establish owners and timelines, escalate material risks with recommendations, and confirm resolution with the site.
  • Own site-facing training, onboarding, and capability-development strategy.
  • Develop and maintain a role-based learning framework covering new-hire onboarding, research-process and system readiness, study-specific preparation, leadership development, and ongoing professional growth.
  • Partner with subject-matter experts and practice leaders to develop and deliver training, and establish measures of participation, adoption, competency, and operational impact.
  • Lead the development, launch, and stabilization of new or expanding site-level research programs by assessing readiness, establishing infrastructure and operating plans, defining milestones, and building sustainable research capabilities.
  • Maintain an integrated view of site priorities, capacity, performance, and emerging risks, and translate site intelligence and performance data into recommendations for operational, portfolio, and investment decisions.
  • Partner across the organization to clarify ownership and handoffs, coordinate support for practices, resolve cross-functional barriers, and ensure commitments to sites are fulfilled.
  • Identify and leverage expertise across the network by sharing effective practices, creating peer-learning opportunities, and building collaboration and knowledge-exchange mechanisms among research leaders.
  • Develop and monitor performance measures, identify trends and opportunities, and provide actionable reporting to leadership and stakeholders.
Desired Qualifications
  • A master’s degree is preferred.
  • Oncology experience in clinical research is preferred.
  • Oncology experience in patient enrollment strategy and patient recruitment is preferred.

About the company

OneOncology builds a network of US oncology practices by partnering with community clinics to broaden access to advanced cancer care. It supports partner sites by investing in clinical, operational, and technical capabilities and by providing a shared data analytics and technology platform to improve care and efficiency. Local practice leadership stays in place, preserving continuity and local expertise while gaining access to centralized resources. The goal is to improve patient outcomes in community settings and sustain high-quality, locally led oncology services by coordinating care through a data-driven platform.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$685M

Headquarters

Nashville, Tennessee

Founded

2018

Get referred to OneOncology

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cencora closed its majority acquisition on February 2, 2026, adding balance-sheet power and distribution leverage.
  • Aug. 18, 2026 disease-group expansion and OpenEvidence integration deepen clinical specialization and workflow stickiness.
  • OneR delivered 23 ASCO 2025 abstracts, proving research output that attracts practices and patients.

What critics are saying

  • Lewis v. OneOncology filed March 31, 2026 and the 401(k) class action hit March 20, 2026.
  • Cencora control after February 2026 threatens physician autonomy, accelerating partner defections over the next 12 months.
  • If network doctors leave for rival platforms, OneOncology loses referral density and the whole MSO model breaks.

What makes OneOncology unique

  • Physician-led network kept local leadership, even after Cencora closed majority control in February 2026.
  • OneOncology embedded OpenEvidence across workflows on August 6, 2026, pairing care, evidence, and trials.
  • Its 2,300-plus providers treat 1.5 million patients across 20 states, giving rare community scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

1%
HealthTech HotSpot
Aug 6th, 2026
OneOncology and openevidence partner to improve cancer care nationwide.

OneOncology and openevidence partner to improve cancer care nationwide. MIAMI & NASHVILLE, Tenn.-(BUSINESS WIRE)-#Oncology-OpenEvidence, the most widely used AI-powered medical search and clinical decision-support platform, and OneOncology, a physician-led national platform empowering independent medical specialty practices, today announced a partnership to embed OpenEvidence into certain clinical applications used across OneOncology's platform to enable physicians to use OpenEvidence for clinical evidence retrieval, reference and research. The integration is designed to make it easier for physicians at OneOncology partner practices to access OpenEvidence directly within their clinical workflows. Over time, the collaboration is expected to expand to include deeper integration with OneOncology's structured genomic data assets and clinical trials matching systems - further aligning evidence, precision oncology insights, and research opportunities at the point of care. In the United States, more than half of hematology/oncology physicians already use OpenEvidence to help inform their clinical decisions. Community physicians at OneOncology partner practices deliver modern, high-quality care to 1.5 million patients nationwide. More than 50 percent of cancer patients in the United States receive their care in community oncology practices. Community physicians manage hundreds of approved therapies across dozens of tumor types, navigate biomarker-driven treatment algorithms that shift with each new approval, and increasingly offer clinical trials that were once limited to academic centers. "Independent physicians across the OneOncology network treat a wide array of cancers across stages, bringing the latest research and treatment options to patients close to home," said Davey Daniel, MD, OneOncology's Chief Medical Officer. "As physicians who read constantly and stay engaged with emerging science, OpenEvidence will help our partners efficiently access the latest, best-available research and evidence, improving the physician experience and supporting better patient outcomes." "Integrating OpenEvidence directly into my workflow will make it easier to access the information I need at the point of care," said Emily Z. Touloukian, DO, FASCO, President and CEO of Coastal Cancer Center in Myrtle Beach, SC. "Oncology is where the information problem in medicine is most acute: the literature moves fast, treatment decisions are increasingly personalized, and the stakes are as high as they get," said Dr. Travis Zack, Chief Medical Officer of OpenEvidence. "OneOncology's partner practice physicians have built a network that brings clinical trials, leading treatment pathways and physician-led innovation into the community. Building OpenEvidence directly into that workflow means the latest evidence, OneOncology's treatment pathways and relevant trials all converge at the point of care." About OpenEvidence OpenEvidence is the fastest-growing and most widely-used clinical decision support platform and medical search engine among U.S. clinicians. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is actively used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com. About OneOncology OneOncology was founded by community physicians, for community physicians, with the mission of improving the lives of everyone living with cancer and other diseases. Its goal is to enable community medical practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports its platform of community medical practices through group purchasing, operational optimization, practice growth, and clinical innovation. Its partner practices comprise approximately 2,300+ providers who care for approximately 1.5 million patients across 20 states. To learn more, visit oneoncology.com.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Business Wire
Dec 16th, 2025
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does...

StockTitan
Dec 15th, 2025
Cencora to acquire OneOncology for $3.6B, raising long-term EPS guidance to 10-14%

Cencora has entered into a definitive agreement to acquire the majority stake it doesn't own in OneOncology, a physician-led oncology management services organisation, from TPG. The transaction values OneOncology's enterprise at $7.4 billion, with Cencora paying approximately $5 billion in total cash consideration, including debt retirement. OneOncology has grown substantially since Cencora's initial investment, attracting leading practices through its physician-led approach. The acquisition will strengthen Cencora's specialty solutions and enhance patient access to pharmaceuticals across communities. The deal is expected to close by the end of Cencora's fiscal 2026 second quarter, subject to regulatory approvals. Cencora plans to fund the transaction through new debt financing and expects the acquisition to be approximately neutral to adjusted diluted EPS in the first twelve months. The company has raised its long-term guidance to reflect OneOncology's expected contribution.

PR Newswire
Oct 8th, 2025
OneOncology Acquires GenesisCare in Florida

OneOncology has expanded in Florida by acquiring GenesisCare and will relaunch as SunState Medical Specialists. The acquisition includes over 100 physicians specializing in urology, oncology, and surgical fields, providing care across Florida. Significant investments are planned to upgrade technology and expand access to advanced clinical services.